MedReleaf positioned as one of Canada's leading exporters of medical
cannabis
MARKHAM, ON, July 11, 2018 /CNW/ - MedReleaf Corp. (TSX:LEAF)
("MedReleaf" or the "Company") today announced that it has received
certification under the European Medical Agency's Good
Manufacturing Practices ("EU GMP") Standards for its Markham facility from authorities in
Cologne, Germany to make a first
export of its products into Germany and has completed its first shipment
of medical cannabis to Cannamedical Pharma GmbH
("Cannamedical").
"With the completion of our first shipment to Germany and ongoing shipments scheduled,
MedReleaf is already among the leading exporters of cannabis to the
European Union," said Neil Closner,
CEO of MedReleaf. "Demand for medical cannabis in Germany far exceeds available supply, and with
production, processes and requisite certifications for commercial
scale exports in place, we are well positioned to expand our
footprint in the EU and drive expanded access for patients around
the world to MedReleaf's premium medical cannabis products."
Cannamedical Pharma is a pioneer in the German medical cannabis
industry and a leading medical cannabis distributor to pharmacies
in Germany with the fastest
growing network of more than 2,100 cannabis distributing pharmacies
across the country.
"We found a strong Canadian partner in MedReleaf to deliver high
grade medical Cannabis products for the German market, that fulfill
Cannamedical's quality standards. Proving Cannamedical's ability to
import medical cannabis from outside of the European Union
strengthens our plans for future growth within the European Union,"
said David Henn, CEO of Cannamedical
Pharma. "Working together to help MedReleaf receive its EU GMP
certification also underlines our high level of
professionalism."
Germany is poised to become the
largest federally regulated medical cannabis market in the world,
with a population of over 82 million, approximately 89% of whom are
covered by the public health insurance program and the remainder
covered by private insurance plans. The current medical cannabis
laws in Germany came into effect
on March 10, 2017 and without
domestic production, cannabis is being imported to meet the rapidly
growing demand.
About MedReleaf (TSX:LEAF)
Canada's most awarded licensed
producer, MedReleaf is an R&D-driven company dedicated to
innovation, operational excellence and the production of industry
leading, top-quality cannabis. Sourced from around the world and
carefully cultivated in one of two state-of-the-art ICH-GMP and ISO
9001 certified facilities in Ontario, with a third facility currently in
development, a full range of premium MedReleaf products are
delivered to the global medical market. We serve the therapeutic
needs of patients seeking safe, consistent and effective medical
cannabis and provide a compelling product offering for the
adult-use recreational market.
For more information on MedReleaf, its products, research
and how the company is helping patients #livefree, please visit
MedReleaf.com or follow @medreleaf
About Cannamedical Pharma GmbH
Pioneering in the German cannabis industry, Cannamedical has
been one of the first to specialize in highly efficient pharma
distribution and marketing in accordance with the narcotics
regulations. The privately-owned, GDP certified company holds
all licenses required for medical cannabis import to Germany, distribution and export within the
European Union. Cannamedical, as independent wholesaler has
expertise in cannabis products and is serving an established and
growing network of pharmacies all around the country. Cannamedical
is ideally positioned in the market with the ability to deliver all
orders in Germany within 24
hours.
Forward Looking Statements
This press release contains "forward-looking information" within
the meaning of applicable Canadian securities legislation which are
based upon MedReleaf's current internal expectations, estimates,
projections, assumptions and beliefs and views of future events.
Forward-looking information can be identified by the use of
forward-looking terminology such as "expect", "likely", "may",
"will", "should", "intend", "anticipate", "potential", "proposed",
"estimate" and other similar words, including negative and
grammatical variations thereof, or statements that certain events
or conditions "may", "would" or "will" happen, or by discussions of
strategy. Forward-looking information include estimates, plans,
expectations, opinions, forecasts, projections, targets, guidance
or other statements that are not statements of fact.
Any forward-looking information speaks only as of the date on
which it is made, and, except as required by law, MedReleaf does
not undertake any obligation to update or revise any
forward-looking information, whether as a result of new
information, future events or otherwise. New factors emerge from
time to time, and it is not possible for MedReleaf to predict all
such factors. When considering these forward-looking statements,
readers should keep in mind the risk factors and other cautionary
statements in MedReleaf's Annual Information Form dated
June 18, 2018 and filed with the
applicable Canadian securities regulatory authorities on SEDAR at
www.sedar.com. The risk factors and other factors noted in
MedReleaf's Annual Information Form could cause actual events or
results to differ materially from those described in any
forward-looking information.
SOURCE MedReleaf Corp.